



# Lipidose™

**A Novel Synergistic Approach – Lipidose™ + Antibiotics  
The Future of Gram-Negative Infection Management:**

**Investor Presentation**

May 2025

CONFIDENTIAL

# The Problem: Gram-Negative CRBSI

## Gram-negative CRBSI & The Endotoxin Challenge

### CRBSI: A Significant Clinical Challenge

**12 - 25%**

Mortality Rate

**\$34k - \$71k**

Cost Per Episode

**7 - 14 Days**



Extended Hospital Stay

### U.S. Market Focus:

- › 100,000 annual Gram-negative CRBSI cases
- › 25% of total CRBSIs in the United States
- › Global market in the low millions of cases

### The Endotoxin Challenge:

- ⚠ Standard antibiotics don't address endotoxin (LPS) released from bacteria
- ⚠ LPS is a key driver of inflammation and sepsis progression
- ⚠ Bacterial killing by antibiotics can **increase LPS release**, potentially worsening inflammation



# Our Solution: Lipidose™ Targets the Root Cause

## Our Solution: Lipidose™

### Novel LPS-Binding Technology

#### 1 Targets Root Cause

Specifically binds and neutralizes circulating LPS (endotoxin) in the bloodstream

#### 2 Synergistic Therapy

Complements antibiotics by counteracting the endotoxin surge released when bacteria are killed

#### 3 Early-Stage Focus


Targets early-stage Gram-negative infections before progression to sepsis

### Key Differentiation:

- **First therapy** to specifically target systemic endotoxin in early infections
- Protein-free phospholipid emulsion that **enhances the body's natural defenses**
- Addresses the **critical gap** in current CRBSI management

### Mechanism of Action


#### 1. Gram-negative Infection



Bacteria release LPS during growth and when killed by antibiotics, triggering inflammation


#### 2. Lipidose™ Administration

##### Lipidose™ Administration



Intravenous liposomal formulation enters bloodstream, interacts with natural HDL particles

#### 3. LPS Binding & Neutralization



Lipidose™-enhanced HDL captures and neutralizes circulating LPS, preventing TLR4 activation

#### 4. Improved Clinical Outcomes

Reduced inflammation leads to faster recovery, decreased risk of sepsis, and potentially shorter hospital stays



Normalized vessel

# Our Solution: Lipidose™ - Targeted Early Intervention



## Lipidose™

Intravenous liposomal formulation

A novel, liposome-based therapeutic agent specifically designed to target and neutralize bacterial endotoxin (LPS) in the bloodstream.



IV Administration

High LPS Affinity

Favorable Safety Profile

### Composition

Protein-free phospholipid emulsion designed to enhance HDL's capacity to bind and neutralize bacterial endotoxins



**Phospholipids**  
Primary functional component




**Plant Oils**  
Provides stability



**Stabilizers**  
Ensures integrity

\*Contains standard pharmaceutical excipients including buffering agents

## Mechanism of Action: LPS Neutralization



Bacteria

LPS (Endotoxin)

### How Lipidose™ Works

- 1 Enhances HDL's natural ability to bind and neutralize LPS
- 2 Counteracts endotoxin surge released when antibiotics kill bacteria
- 3 Prevents inflammatory cascade by removing LPS trigger



## Strategic Positioning

### Synergistic with Antibiotics

Directly addresses and neutralizes endotoxin (LPS), a critical inflammatory mediator that antibiotics alone do not manage and can inadvertently increase.

### Enhances Treatment Efficacy and Safety

By mitigating LPS-driven inflammation and its downstream consequences, Lipidose™ aims to improve overall clinical outcomes and potentially reduce complications associated with severe infections and necessary antibiotic therapy.

### Treatment Comparison








#### Standard Antibiotics

- Effectively kills bacteria
- Releases endotoxin (LPS) during bacterial lysis
- Does not address inflammatory response

#### Lipidose™ + Antibiotics

- Combines bacterial killing with endotoxin neutralization
- Mitigates inflammatory triggers
- Addresses both cause and consequence

## Lipidose™ Mechanism of Action: Targeted Endotoxin Neutralization

Gram-negative Infection Pathway	<b>Gram-negative Bacterial Infection</b>  <p>Gram-negative bacteria contain LPS in outer membrane</p>	<b>Antibiotic-Induced LPS Release</b>  <p>Antibiotics release LPS, triggering inflammatory cascade via TLR4/MD-2</p>	<b>Lipidose™ Mechanism</b>  <p>Lipidose™ enhances HDL's endotoxin-binding capacity, preventing TLR4 activation</p>	<b>Clinical Outcomes</b>  <ul style="list-style-type: none"> <li>□ Reduced inflammatory cytokines</li> <li>□ Hospital stays reduced by 2-4 days</li> </ul>
Gram-positive Infection Pathway	<b>Gram-positive Bacterial Infection</b>  <p>Gram-positive bacteria lack LPS but release other inflammatory components</p>	<b>Antibiotic Treatment</b>  <p>Antibiotics effective; inflammatory response primarily from cell wall fragments</p>	<b>Standard Treatment Sufficient</b>  <p>Peptidoglycan fragments</p> <p>Standard antibiotics typically sufficient; no endotoxin-mediated cascade</p>	<b>Lipidose™ Targeting</b>  <p>Lipidose™ specifically targets the endotoxin-mediated pathology unique to gram-negative infections</p> <p>→ Selective endotoxin binding</p> <p>→ No effect on gram-positive treatment</p>

# Lipidose™: A Compelling Value Proposition Addressing Critical Unmet Needs

## Lipidose™ Value Drivers

### ✓ Improved Clinical Outcomes:

Potential reduction in sepsis progression, organ damage, and mortality.

### ✓ Reduced Length of Stay:

Potential reduction in ICU and total hospital days (2-4 days shorter).

### ✓ Cost Savings:

Lower total cost of care through faster recovery and fewer complications.

### ✓ Non-Invasive Administration:

Simple IV delivery, no specialized equipment required.

### ✓ Early Intervention Advantage:

Targets LPS before sepsis progression.

### ✓ Synergistic with Antibiotics:

Counteracts antibiotic-induced LPS release.

### ✓ Unmet Need Addressed:

First therapy specifically targeting systemic endotoxin effects in early infection.

## Competitive Advantage vs. Existing Approaches

FEATURE	LIPIDOSE™	COMPETITORS (PMX-HP/OXIRIS)
Administration	Simple IV infusion	Invasive extracorporeal circuits
Timing	Early infection	Late-stage sepsis/ICU
Cost	<\$5k/course projected	\$15k+/treatment
Setting	Standard hospital ward	ICU/critical care only
Workflow	Complements standard care	Requires specialist monitoring
Target Population	All CRBSI patients	Critical sepsis cases only



Targeting a significant unmet need in early Gram-negative infection management creates an attractive commercial opportunity with substantial upside potential.

## Lipidose™ + Antibiotics: Projected Clinical & Economic Advantages


Detailed economic benefits and clinical outcomes for healthcare systems

### Economic Value Proposition

#### Cost Comparison Analysis

**Standard: \$45K-\$75K+**

→ **With Lipidose™: \$15K-\$30K**



#### Projected Net Savings Per Case:

**\$25,000 - \$45,000+**

Based on prevention of sepsis progression and reduced hospital stays

### Clinical Benefits & Implementation

#### Key Clinical Advantages



##### Dual Action Mechanism

Bacterial eradication + endotoxin neutralization



##### Reduced Inflammatory Response

Attenuated IL-6 and TNF-alpha levels



##### Shortened Hospital Stays

Potentially reduced ICU requirements

#### Implementation Timeline

- Initial Clinical Integration  
Protocol development and medical staff training
- Early Intervention Protocol  
GNBSI identification and rapid Lipidose™ administration
- Outcomes Monitoring  
Tracking reduction in sepsis progression and cost savings

### Healthcare System Impact & Next Steps

#### Strategic Implementation Benefits

Metric	Current Standard	With Lipidose™ Therapy
Sepsis Progression Rate	Significant risk	Potentially reduced
Length of Hospital Stay	10-21+ days with ICU	Potentially shortened
Mortality Risk	Elevated with severe sepsis	Potentially lowered

#### Next Steps


- ✓ Complete pivotal clinical trials
- ✓ Develop implementation protocols
- ✓ Establish early GNBSI intervention guidelines
- ✓ Create pharmacoeconomic outcome metrics

\*Projections are based on Lipidose™'s therapeutic hypothesis, its specific mechanism of action, preclinical data, and development program objectives. Definitive demonstration of clinical efficacy is subject to completion and positive results from ongoing and planned pivotal clinical trials.

# Market Opportunity



## Global CRBSI Treatment Market



Gram-negative CRBSI (~25% of total) represents a focused target for Lipidose™

- 💡 Significant growth potential driven by increasing catheter usage in aging populations, rising healthcare-associated infections, and growing awareness of infection management.

## \$ High-Cost Burden


### Hospital Costs Per CRBSI Episode



### Extended Hospital Stay



### Mortality Rate



Gram-negative cases associated with higher costs and mortality versus gram-positive

## Development & IP Strategy

### Development Plan:

- Phase 2b trial with biomarker endpoints
- Phase 3 trial with clinical endpoints for FDA approval

### Intellectual Property:

- Core patent protection until 2032
- Strategy to extend exclusivity beyond 2032

## Regional Market Distribution & CRBSI Types



■ North America  
■ Europe  
■ Rest of World

### Gram-Negative CRBSI

- Represents ~25% of CRBSI cases
- Key pathogens: *E. coli*, *Pseudomonas*, *Klebsiella*
- Releases endotoxin (LPS) during growth and when killed by antibiotics
- Primary target for Lipidose™ due to endotoxin-driven inflammation

### Gram-Positive CRBSI

- Represents ~75% of CRBSI cases
- Primarily caused by *Staphylococcus* species and *Enterococcus*
- Less associated with endotoxin-driven inflammation
- Different pathogenic mechanisms than gram-negative infections

### Comparison

While gram-positive CRBSI is more common, gram-negative cases typically result in higher mortality rates and treatment costs due to endotoxin-mediated complications.

Gram-negative  
Higher treatment costs

Gram-negative  
Increased mortality risk

## Value Proposition

Lipidose™ addresses a clear therapeutic gap and offers substantial value to healthcare systems and patients:

- ✓ **Improved Clinical Outcomes:**  
Potential reduction in sepsis progression, organ damage, and mortality
- ✓ **Reduced Length of Stay:**  
Potential reduction in ICU and total hospital days
- ✓ **Cost Savings:**  
Lower total cost of care for CRBSI episodes through faster recovery and fewer complications
- ✓ **Unmet Need Addressed:**  
First therapy specifically targeting systemic endotoxin effects in early infection
- ✓ **Expansion Potential:**  
Initial focus on gram-negative CRBSI with clear pathway to other gram-negative infections where endotoxin plays a significant role

- ⌚ Targeting a significant unmet need in a growing market creates an attractive commercial opportunity with substantial upside potential.

# Competitive Landscape: Clear Differentiation in Systemic Endotoxin Targeting

## Existing/Experimental Approaches

### Extracorporeal Blood Purification

#### Polymyxin B Hemoperfusion (PMX-HP):

- Used since 1994 for endotoxic shock in ICU
- Requires invasive blood purification
- Mixed efficacy in clinical trials
- Limited to critical care settings

### Dialysis-Based Systems

#### OXIRIS Filter & similar technologies:

- Combines endotoxin/cytokine adsorption
- Requires dialysis infrastructure
- Used only in AKI/septic shock patients
- Substantial cost and complexity

### Failed Late-Stage Approaches

#### Anti-TNF/IL-1 antibodies, TLR4 antagonists (Eritoran):

- Failed due to heterogeneous populations
- Late intervention timing
- Complex sepsis pathophysiology

## Strategic Positioning

### White Space

First IV therapy targeting LPS in early Gram-negative infections, creating a unique positioning where no direct competitors exist.

### Clinical Advantage

Complements antibiotics without requiring ICU-level care, allowing for broader application across standard hospital settings.

### Learning from Past Failures

Avoids pitfalls of failed late-stage anti-inflammatory/TLR4 antagonist approaches by focusing on early intervention in a more defined population.

### Regulatory Pathway

Focus on biomarker-driven CRBSI endpoints helps avoid challenges of sepsis trial heterogeneity that derailed previous therapies.

## Lipidose™ Differentiation

FEATURE	LIPIDOSE™	EXTRACORPOREAL COMPETITORS
Mechanism	IV liposomal HDL enhancement	Extracorporeal adsorption
Timing	Early intervention (pre-sepsis)	Late-stage critical care
Administration	Non-invasive (IV)	Invasive (requires vascular access)
Target Population	CRBSI patients pre-ICU admission	ICU patients with organ failure
Synergy with Antibiotics	Neutralizes antibiotic-induced LPS surge	No direct synergy demonstrated
Cost/Complexity	\$ Low (\$/dose)	\$ \$ \$ High (\$15k+/treatment + specialist labor)

## Intellectual Property Position

### Core Exclusivity


Lipidose™ is protected by a robust patent portfolio centered on a key active ingredient:

#### Market Exclusivity Until 2032

Key active ingredient patent protection in the US provides strong barrier to entry

#### Generic Competition Barrier

Effectively blocks generic competition during critical development and initial commercial phases



💡 Core patent creates foundational protection while Lipidose™ completes development and enters market

### Future Exclusivity Strategy

Strategic plan to extend protection beyond the core patent expiration:

#### New Method-of-Use Patents

Focus on obtaining patents specifically covering treatment of early-stage Gram-negative infections/CRBSI with Lipidose

Potential to extend exclusivity well beyond 2032


#### LPS-Binding Mechanism

Leverage the novel application of Lipidose's mechanism in early infection settings to strengthen patentability

*Demonstrating novelty and non-obviousness for the new method*

⚠️ **Patent Term Extension Limitations:** Extending existing patents based on the new indication is unlikely due to "first permitted commercial use" rule

### IP Protection Timeline



### IP Strategy Advantages

#### Immediate Protection

Existing active ingredient patent provides strong foundation during critical development phase

#### Layered Strategy

Multiple layers of IP protection create robust barriers to competition

#### Extended Runway

Method-of-use patents could potentially extend exclusivity beyond 2040


💡 Our IP strategy provides strong current protection with a clear path to extending market exclusivity, supporting long-term value creation

# Clinical Development Plan



## Overall Goal

Demonstrate safety and efficacy of Lipidose™ as synergistic therapy in early-stage Gram-negative infections (starting with CRBSI)



## Phase 1: Completed

- Safety & Tolerability
- PK/PD Assessment
- Dose Range Finding

### Results Highlight:

Favorable safety profile established with no significant adverse events observed across tested dose ranges



## Phase 2b: Current Focus

- Design:** Randomized, double-blind, placebo-controlled
- Population:** Early CRBSI patients with confirmed Gram-negative infection
- Intervention:** Lipidose + Standard antibiotic therapy vs. Placebo + Standard antibiotic therapy
- Primary:** Change from baseline in LPS/Endotoxin Activity
- Secondary:**
- Change in key inflammatory cytokines (IL-6)
  - Progression to septic shock



## Phase 3: Planned

- Design:** Larger randomized, double-blind, placebo-controlled trial(s)
- Population:** Expanded population of CRBSI patients with Gram-negative infections
- Primary:** Clinical Outcome - Composite endpoint (clinical cure, complication reduction)
- Secondary:**
- Hospital length of stay
  - ICU length of stay
  - Resolution of LPS-mediated inflammation

### ⟳ Synergy Evaluation

Trial includes metrics to assess how Lipidose improves outcomes by neutralizing the additional LPS released during antibiotic-induced bacterial lysis



## Safety Profile & Synergistic Mechanism

Favorable safety profile established in Phase 1 supports progression to efficacy trials. The clinical development program is specifically designed to demonstrate how Lipidose™ enhances antibiotic effectiveness by neutralizing the increased LPS released when bacteria are killed, creating a true complementary therapy approach.

## Approval Target

Our regulatory strategy is focused on securing:

### FDA Approval for:

**Adjunctive treatment of early-stage Gram-negative infections**

*Initial focus: Catheter-Related Bloodstream Infections (CRBSI)*



**Positioning as a synergistic therapy (used with antibiotics) streamlines regulatory pathway by leveraging established antibiotic efficacy**

## Biomarker Strategy

Utilize biomarkers as pharmacodynamic endpoints in Phase 2b to demonstrate biological activity:

LPS

### Lipopolsaccharide (Endotoxin)

Direct measure of Lipidose™'s primary target

IL-6


### Interleukin-6

Key inflammatory cytokine induced by LPS

TNF-

### Tumor Necrosis Factor-alpha

Early mediator of inflammation triggered by LPS



Long-term goal: Explore potential for biomarker qualification as surrogate endpoint (requires extensive validation)



## FDA Engagement Strategy

Proactive communication with FDA is critical to align on trial design, endpoints, and overall strategy:

1

### Pre-IND Meeting

Initial alignment on development program and preclinical requirements

2

### End of Phase 1 Meeting

Review safety data and confirm Phase 2 design

3

### End of Phase 2 Meeting

Critical milestone to align on Phase 3 design and endpoints

4

### Pre-NDA/BLA Meeting

Ensure submission package meets requirements



## Expedited Pathways

Leverage potential to address unmet medical need in serious infections to explore:



### Fast Track Designation

Eligibility supported by targeting serious infections with unmet medical need

Benefits: Rolling review, more frequent FDA interactions



### Priority Review

Potential 6-month review timeline vs. standard 10-month review

Requires showing significant improvement in treatment



### Limited Population Pathway (LPAD)

Potentially applicable based on targeting specific patient population  
Streamlined development for targeted antimicrobial products



### Accelerated Approval

Potential if strong biomarker data and FDA agreement

Requires post-approval study to confirm clinical benefit

## Target Audience

Lipidose™ will primarily target hospital settings where catheter-related infections are most prevalent:

### Critical Care Units (ICUs)


High concentration of central lines with vulnerable patients

### Specialty Wards

Oncology, Total Parenteral Nutrition (TPN), and Hemodialysis units

### Key Decision Makers

Infectious disease specialists, intensivists, hospital pharmacists



## Value Drivers

### Improved Clinical Outcomes

Reduced complications and faster resolution of infection

### Reduced Length of Stay

Potential reduction in hospital/ICU length of stay

### Cost Savings

Lower total treatment costs through faster recovery and fewer complications

💡 Each day of reduced hospital stay saves approximately \$2,000-4,000 per patient

## Market Positioning

First-in-class, systemic adjunctive therapy complementing antibiotics by targeting endotoxin effects

Differentiated positioning in the marketplace:

### Novel Mechanism

Targets LPS specifically, unlike any current therapy

### Complementary Approach

Works with standard antibiotics to enhance overall efficacy

### Early Intervention Focus

Addresses infection before progression to severe sepsis

### Unique Value Proposition

## Commercialization Model & Market Access

Two potential commercialization approaches:

VS



### Internal Team

- + Full control over messaging & strategy
- + Build specialized expertise
- Higher upfront investment



### Strategic Partnership

- + Leverage existing relationships
- + Faster market penetration
- Revenue sharing

Market Access Strategy:



### Pharmacoeconomic Data

Generate robust cost-effectiveness evidence



### Early Payer Engagement

Align on value metrics & pricing strategy



### Formulary Strategy

Position for P&T committee approval

# Lipidose™: 3-5 Year Financial Projections & ROI

## Market Opportunity

### US Market

- ~100,000 annual Gram-negative CRBSI cases (25% of total CRBSI)
- \$34,000-\$71,000 cost per episode Direct hospital expenses
- 12-25% attributable mortality rate 7-14 additional hospital days per episode

### Global Market

- \$1.6B (2024) → \$2.5B (2030)  
CAGR ~5-6%
- Gram-negative CRBSI segment  
Highest-cost and highest-mortality segment

## Projected Revenue & Adoption



YEAR	MARKET %	PATIENTS	REVENUE
2026	5%	5,000	\$75M-\$150M
2027	10%	10,000	\$150M-\$300M
2028	15%	15,000	\$225M-\$450M
2029	18%	18,000	\$270M-\$540M
2030	20%	20,000	\$300M-\$600M

US-only projections; global revenues could be 2-3x higher with successful international launches and label expansions.

**Pricing:** \$15,000-\$30,000 per treatment course  
Based on projected net savings and value-based pricing structure

## Health Economic Impact



### Cost Savings

\$25,000-\$45,000 per case

Based on prevention of sepsis progression and reduced hospital/ICU stays



### Clinical Impact

Reduced sepsis progression  
2-4 days shorter hospital stays

Each day of reduced stay saves \$2,000-\$4,000 per patient

## Key Development Milestones

- 2025**  
Phase 2b trial initiation
- 2026**  
Phase 2b data readout & FDA meeting
- 2027-2028**  
Phase 3 trial & FDA submission
- 2028-2029**  
US launch & initial revenue
- 2030+**  
Market expansion & international launches

## ROI Potential

### High-Value Niche

Targeting a high-cost, high-mortality patient segment with no direct competitors addressing systemic endotoxin in early infection.

### Premium Pricing Justification

Strong pharmacoeconomic value due to cost offsets (reduced LOS, complications). Payer interest likely if clinical benefits demonstrated.

### IP Protection

Core patent protection until 2032, with strategy for method-of-use patents to extend exclusivity beyond 2040.



**Lipidose™ offers a compelling ROI profile** by addressing a critical unmet need, delivering substantial clinical and economic value, and capturing a significant share of a growing market.

# The Ask

## Funding Request

To advance our first-in-class endotoxin neutralizer through Phase 2b validation and position for Phase 3 success

### Funding Allocation



● Phase 2b Clinical Trial	\$40M (33%)
● Phase 3 Preparation	\$25M (21%)
● Manufacturing/CMC	\$28M (23%)
● Regulatory/Pre-Commercial	\$17M (14%)
● Contingency	\$10M (8%)

**Pre-money valuation:**  
**\$250-350M (2.5-3.5x forward revenue multiple)**

### Strategic Deployment & Value Inflection

#### 12-18 Months

Phase 2b topline data (LPS/IL-6 reduction)

#### 24-30 Months

Phase 3 initiation pending FDA alignment

#### 36-48 Months

NDA/BLA submission

**Exit potential with successful Phase 2b:  
\$800M-\$1.2B valuation**

**Path to exit:  
Strategic acquisition (2028-2030) at \$2.5-\$3.5B**

**Projected ROI Multiple:  
20-30x**

24-36 month runway to key value catalysts  
Aligned with 2025 biotech funding trends for infectious disease assets



# Summary & Investment Highlights

"Lipidose™ **Potential to expand beyond CRBSI to broader Gram-negative infections, significantly increasing market reach.**"

## ① Compelling Unmet Need

- ✓ CRBSI causes 12-25% mortality rate with high costs (\$34-71k per episode)
- ✓ No approved therapies target systemic endotoxin neutralization in early infection
- ✓ Antibiotics alone don't address endotoxin-driven inflammation

## 💡 Novel, Targeted Approach

- ✓ Proprietary liposomal technology specifically binds and neutralizes LPS
- ✓ Adjunctive therapy to antibiotics targeting early-stage infection
- ✓ Avoids pitfalls of previous late-stage sepsis interventions

## ↳ Significant Market Opportunity

- ✓ CRBSI treatment market: ~\$1.6B (2024), growing to ~\$2.5B (2030s)
- ✓ Potential to expand beyond CRBSI to broader Gram-negative infections
- ✓ Value drivers: improved outcomes, reduced LOS, cost savings

## 🧪 Clear Development Pathway

- ✓ Focused Phase 2b trial with biomarker endpoints (LPS/cytokine reduction)
- ✓ Streamlined Phase 3 program with clinical endpoints for approval
- ✓ Potential for expedited regulatory pathways (Fast Track, Priority Review)

## 🛡️ Strong Foundational IP

Core patent protection until 2032 with strategy to extend exclusivity via method-of-use patents well beyond 2032



## 👤 Experienced Team

Led by industry veterans with proven track records in:

Pharmaceutical Development      Infectious Disease  
Liposomal Technology      Commercial Launch      Regulatory Affairs



# Sepsicure

We welcome your inquiries about Lipidose™ and investment opportunities



Company  
**Sepsicure, LLC**



Email  
[Investor.relations@lipidose.com](mailto:Investor.relations@lipidose.com)



Phone  
**+1 (555) 123-4567**



Website  
[www.lipidose.com](http://www.lipidose.com)

**Disclaimer:**

This presentation contains forward-looking statements that involve risks and uncertainties. Actual results may differ materially from those projected in the forward-looking statements. The company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this presentation.